Well, if we had started a placebo/booster in November when the signal emerged, we'd be halfway to a better answer. I realize it's not easy, but given the stakes the best answers are speed up production (make the trade-off moot) and collect data (make the trade-off informed).
If rich countries can do with less, supply (of other vaccines) for poorer countries will be more. I didn't say there was an excess now because there's clearly a shortage now *everywhere*, and hence the painful discussions of trade-offs, but it's pretty straightforward.
-
-
Again, I think you're overly optimistic about liquidity in the vaccine market.
-
Not the way things are, you are right. But the way things are is pretty terrible. I'm pointing out that equity is not at all on one side of the trade-off debate. Ideally, yeah, we increase the supply of stable/easier one-dose vaccines and do away with the trade-off. Of course.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.